NCT05389319View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

PHASE1SuspendedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
COVID-19
Interventions
BIOLOGICAL

Prime-2-CoV_Beta

1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1

Trial Locations (2)

20359

Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

72074

University Hospital Tübingen, Institute of Tropical Medicine, Tübingen

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

collaborator

VisMederi srl

INDUSTRY

collaborator

Staburo GmbH

INDUSTRY

collaborator

Viedoc Technologies AB

UNKNOWN

lead

University Hospital Tuebingen

OTHER